OCEAN

Brief description of study

The aim of the study is to investigate the efficacy and safety of depemokimab compared with mepolizumab in participants with relapsing or refractory EGPA receiving SoC therapy. Participants will receive subcutaneous injections of depemokimab/placebo or mepolizumab/placebo every 4 weeks for a 52 week intervention period. The study also includes regular blood and urine sampling and spirometry to assess efficacy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 851733

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).